1 tracked superinvestor hold Protagonist Therapeutics Inc (PTGX), worth $17M combined, led by Stanley Druckenmiller. Smart money is holding PTGX as of the latest 13F filings.
Current price
$137.64
+148.8%
1Y
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis,…
Market cap
$6.3B
P/E
-47.99
Div yield
0.0%
Revenue YoY
-89.4%
Analyst target
$117
Snapshot for context. For deep analysis use a stock screener — this page is about who owns it.
Superinvestors holding
1
tracked 13F / N-PORT funds
Combined value
$17M
disclosed long exposure
Tier-1 conviction
1
concentrated holders
Net this quarter
0
0 buying · 0 selling
Smart money is holding PTGX steady this quarter — buys and sells are balanced.
Protagonist Therapeutics Inc (PTGX) is held by 1 tracked funds worth $17M combined, 1 of them concentrated Tier-1 managers whose positions carry real conviction.
The largest position belongs to Stanley Druckenmiller at 0.5% of their book — no single tracked manager treats it as an outsized, top-weighted bet.
Tracked holders were largely static this quarter — no new opens, adds or trims of size — suggesting the position is being held rather than actively traded.
| Investor | Move | % of their portfolio | Position value |
|---|---|---|---|
| Held | 0.5% | $17M |
Tier badge = signal quality: 1 concentrated conviction · 2 quant/multi (context) · 3 retail & diversified. Only Tier 1 holdings feed the consensus signal.
Which superinvestors own PTGX?
1 tracked funds hold Protagonist Therapeutics Inc (PTGX), the largest being Stanley Druckenmiller (Duquesne Family Office) at 0.5% of its 13F portfolio. 1 of them are concentrated Tier-1 conviction managers.
Is smart money buying or selling PTGX?
In the most recent 13F quarter, 0 tracked funds added or opened PTGX and 0 trimmed it.
How much PTGX do tracked funds hold?
Combined disclosed long exposure to PTGX across tracked superinvestors is $17M as of the Mar 2026 filings.
Holdings aggregated from the latest SEC 13F & N-PORT filings via FMP · Mar 2026 quarter. Long equity positions only, reported with up to a 45-day delay — for activity between filings see real-time moves. Not financial advice.